CAJ | 학술논문

肺癌是全球范围内发病率和死亡率最高的恶性肿瘤之一.而非小细胞肺癌(NSCLC)占肺癌的85％,5年生存率仅约为15％.大部分患者就诊时已属晚期,即使有手术机会,40％以上患者也会出现局部复发或远处转移.虽然多学科综合治疗使晚期NSCLC患者的治疗有了较大进步,但仅部分患者显示出较好的临床获益,其治疗效果仍不理想.近年来,随着分子免疫机制的研究进展,过继免疫治疗、靶向免疫治疗、疫苗以及基因治疗等研究取得了很大的进展,为NSCLCS的治疗提供了新的治疗思路.
폐암시전구범위내발병솔화사망솔최고적악성종류지일.이비소세포폐암(NSCLC)점폐암적85％,5년생존솔부약위15％.대부분환자취진시이속만기,즉사유수술궤회,40％이상환자야회출현국부복발혹원처전이.수연다학과종합치료사만기NSCLC환자적치료유료교대진보,단부부분환자현시출교호적림상획익,기치료효과잉불이상.근년래,수착분자면역궤제적연구진전,과계면역치료、파향면역치료、역묘이급기인치료등연구취득료흔대적진전,위NSCLCS적치료제공료신적치료사로.
Lung cancer is the leading cause of cancer death all over the world.Non-small-cell lung cancer (NSCLC) accounts for more than 85％ of lung cancer cases.The five year survival rate of patients with advanced stage NSCLC is less than 15％.The majority of patients are diagnosed at the advanced stage of this disease.Even if there is the chance of operation,more than 40％ of patients also had local recurrence or distant metastasis.Although multidisciplinary treatment has made great progress,few patients showed good clinical benefit.The treatment for advanced NSCLC is still not satisfactory.In recent years,adoptive immunotherapy,targeted immunotherapy,vaccines and gene therapy research has made great progress in the treatment of NSCLC.